Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such
as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making
androgens. Giving bortezomib with hormone therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bortezomib with or without hormone
therapy works in treating patients with relapsed prostate cancer.